|
|
|
| A prospective phase Ⅱstudy of Gabapentin combined with Oxycontin in the treatment of pain in radiation oral mucositis |
| XIA Xiao-long1 ZHANG Wen-ping1 HU Jian-bing2 SHU yun1 WANG Hong-yun1 WANG Xu3 ZOU Cai-liang1 GAN Xiao-ling |
1. The First Department of Abdominal Tumor, the Third People′s Hospital of Jiujiang City, Jiangxi Province, Jiujiang 332000, China;
2. Department of Internal Medicine, De′an County People′s Hospital, Jiangxi Province, De′an 330400,China;
3. Department of Imaging, the Third People′s Hospital of Jiujiang City, Jiangxi Province, Jiujiang 332000, China |
|
|
|
|
Abstract Objective To study the effect of Gabapentin combined with Oxycontin in the treatment of pain in radiation oral mucositis. Methods From May 2019 to September 2020, 58 patients with radiation oral mucositis who were treated in the Third People′s Hospital of Jiujiang City were selected as the research subjects. According to the random number table method, they were divided into control group (29 cases) and treatment group (29 cases). Patients in the control group were treated with Oxycontin, and patients in the treatment group were treated with Gabapentin combined with Oxycontin. Both groups were treated for eight weeks. The pain scores of numeric rating scale (NRS) scores of the two groups were compared before treatment and at 2, 4, 6 and 8 weeks after treatment. The proportions of grade 1-2 and grade 3-4 in oral mucosa radiation injury grading were compared between the two groups after 2 and 8 weeks of treatment. The quality of life 1 week before radiotherapy and the end day of radiotherapy and the incidence of adverse reactions during treatment were compared between the two groups. The total cost of analgesics after treatment was compared between the two groups. Results There was no statistically significant difference in NRS score of patients between the two groups before treatment (P>0.05). The NRS scores of the two groups at 2, 4, 6 and 8 weeks of treatment were lower than those before treatment, with statistically significant differences (P<0.05). The NRS scores of the two groups at 4, 6 and 8 weeks of treatment were lower than those at 2 weeks of treatment, with statistically significant differences (P<0.05). The NRS score of the two groups at 6 and 8 weeks of treatment were lower than those at 4 weeks of treatment, with statistically significant differences (P<0.05). The NRS score of the two groups at the 8 weeks of treatment was lower than that at the 6th week of treatment, the difference was statistically significant (P<0.05). The NRS scores in the treatment group were lower than those in the control group at 2, 4, 6 and 8 weeks of treatment, with statistically significant differences (P<0.05). The proportions of oral mucosal radiation injury grade 1-2 in treatment group at the 2 and 8 weeks of treatment were higher than those in control group, and the differences were statistically significant (P<0.05). The proportions of oral mucosal radiation injury grade 3-4 in the treatment group at 2 and 8 weeks of treatment were lower than those in the control group, and the differences were statistically significant (P<0.05). There was no significant difference in the European Organization for Research and Treatment of Cancer head and neck cancer quality questionnaire (EORTC QLQ-H&N35) score between the two groups one week before radiotherapy (P>0.05). The EORTC QLQ-H&N35 scores at the end of radiotherapy in the two groups were lower than those one week before radiotherapy, the differences were statistically significant (P<0.05). The EORTC QLQ-H&N35 score of the treatment group was lower than that of the control group at the end of radiotherapy, the difference was statistically significant (P<0.05). The total incidence of adverse reactions in the treatment group was lower than that in the control group, and the difference was statistically significant (P<0.05). The total cost of analgesics in the treatment group was less than that in the control group after treatment, and the difference was statistically significant (P<0.05). Conclusion Gabapentin combined with Oxycontin can effectively reduce the pain degree and oral mucosal reactions of patients with radiation oral mucositis, reduce the occurrence of adverse reactions, improve the quality of life, and reduce the economic burden of drugs.
|
|
|
|
|
|
| [6] |
何小红，马柳，李园，等.中药雾化治疗鼻咽癌患者放射性口腔黏膜炎临床研究[J].山东中医杂志，2019，38（11）：1046-1050.
|
| [7] |
王教成，张相国，张群功，等.三参地萸汤联合康复新液在鼻咽癌放疗治疗中的应用及对口腔黏膜反应、细胞免疫功能和生活质量的影响[J].福建医药杂志，2019，41（1）：76-77.
|
| [8] |
段元元.调强放疗与二维常规放疗对鼻咽癌患者生活质量的比较研究[D].济南：山东大学，2019.
|
| [9] |
杨令云.人参多糖针联合西帕依固龈液治疗放射性口腔黏膜炎临床研究[J].中医学报，2017，32（8）：1388-1390.
|
| [1] |
高燕，杨连平.急性放射性口腔黏膜炎的防治研究进展[J].医学综述，2020，26（22）：4494-4498.
|
| [2] |
尹燕，张静平.放射性口腔黏膜炎影响因素研究进展[J].中华放射肿瘤学杂志，2020，29（9）：799-803.
|
| [3] |
杜亚娟，王艺碧，林慧娟.不同给药途径的阿片类止痛药对放射性口腔炎所致重度疼痛的疗效观察[J].当代护士（综合版），2020，27（5）：82-84.
|
| [4] |
左蕾，杨晓秋，周泽军，等.阿片药物联用加巴喷丁治疗中重度癌痛的系统评价[J].中国疼痛医学杂志，2019，25（7）：504-512.
|
| [5] |
中华人民共和国卫生部.放射性口腔炎诊断标准[J].中国农村医学杂志，2005，33（5）：61-62.
|
| [10] |
沈建军，牛维纳，张红雁，等.卡波姆治疗头颈部肿瘤患者放射性口腔黏膜炎的疗效及安全性[J].现代肿瘤医学，2018，26（10）：1508-1512.
|
| [11] |
李桂容，冯惠霞，陈柳，等.奥施康定治疗鼻咽癌放化疗致口腔黏膜炎疼痛的疗效观察[J].护士进修杂志，2015，30（19）：89-90.
|
| [12] |
周海辉，张海霞，钱晓萍，等.加巴喷丁辅助治疗神经病理性癌痛的疗效和安全性[J].中国药师，2019，22（7）：1278-1279.
|
| [13] |
薛钧，刘晶煜，李文娟，等.加巴喷丁对癌性神经病理性疼痛病人阿片耐受指数的影响[J].中国疼痛医学杂志，2019，25（2）：120-124.
|
| [14] |
王斌，李健，刘卫卫，等.放化疗综合治疗对局部晚期鼻咽癌患者机体营养状况及生命质量的影响[J].医学临床研究，2018，35（5）：1002-1004.
|
| [15] |
张力川，王玉洁，庄冰，等.头颈部恶性肿瘤放射治疗患者放射性黏膜炎及其与营养状况的关系[J].中华临床营养杂志，2019，27（6）：367-373.
|
|
|
|
